Core Viewpoint - The article highlights the significant achievements of Innovent Biologics in the field of metabolic disease treatment, particularly through the dual receptor agonist, Ma Shidu Te (MGC/GLP-1), which has shown promising results in clinical trials for type 2 diabetes and weight management [10][12]. Group 1: Clinical Research Achievements - Innovent Biologics announced the publication of two Phase III clinical trial results for Ma Shidu Te in the prestigious journal Nature, marking the first time two such studies in the metabolic and endocrine disease field have been published back-to-back [10][11]. - The DREAMS-1 trial involved 320 participants with type 2 diabetes who did not achieve target results through diet and exercise, showing significant reductions in HbA1c levels with Ma Shidu Te compared to placebo [13][15]. - The DREAMS-2 trial included 731 participants whose blood sugar was poorly controlled on metformin, demonstrating that Ma Shidu Te significantly outperformed the comparator drug in reducing HbA1c levels [14][15]. Group 2: Efficacy and Safety - Ma Shidu Te achieved a 2.02% reduction in HbA1c levels at 24 weeks in the DREAMS-1 trial, with 81.8% of participants in the 6mg group reaching HbA1c levels below 7%, compared to only 11.7% in the placebo group [15]. - In the DREAMS-2 trial, the 6mg group achieved a 1.66% reduction in HbA1c, with 70.4% of participants reaching the same target, indicating strong efficacy in blood sugar control [15][16]. - The overall safety profile of Ma Shidu Te was consistent with previous studies, showing good tolerability and no new safety signals, with gastrointestinal side effects being the most common [19]. Group 3: Broader Implications - The successful results of Ma Shidu Te not only contribute to the treatment of obesity and diabetes but also reflect China's growing capabilities in drug development and innovation on the global stage [10][12]. - The dual receptor mechanism of Ma Shidu Te offers a unique advantage in managing weight and metabolic health, particularly for the Chinese population, which faces specific challenges related to visceral fat accumulation [18]. - The ongoing research and development efforts by Innovent Biologics aim to expand the indications for Ma Shidu Te, further enhancing its role in global diabetes and weight management strategies [12][19].
登顶《Nature》主刊！玛仕度肽两项III期临床成果背靠背同步刊发